Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2026 Ended September 30, 2025 and Provides Conference Call Information
Northvale, New Jersey--(Newsfile Corp. - November 14, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced results for the second quarter of fiscal year 2026 ended September 30, 2025 ("Second Quarter").Consolidated revenues for the three-month period ending September 30, 2025, were $36.3 million, an increase of $17.4 million or approximately 92% as compared to the comparable period of the...
2025-11-14 4:19 PM EST
Elite Pharmaceuticals Receives FDA Approval for Generic Requip XL(R)
Northvale, New Jersey--(Newsfile Corp. - November 12, 2025) - Elite Pharmaceuticals, Inc. (OTCBB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, today announced that it received approval from the US Food and Drug Administration (FDA) for an Abbreviated New Drug Application (ANDA) for a generic version of Requip XL® (Ropinirole Extended-Release Tablets USP), with strengths of 2 mg, 4 mg, 6 mg, 8 mg, and 12 mg tablets. Ropinirole belongs...
2025-11-12 7:00 AM EST
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2026 Financial Results on November 17, 2025
Northvale, New Jersey--(Newsfile Corp. - November 10, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today that the second quarter financial results of the 2026 fiscal year will be released on Friday, November 14, 2025. Elite's management will host a live conference call on Monday, November 17th, at 11:30 AM EST to discuss the company's financial and operating results and provide a...
2025-11-10 7:00 AM EST
Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2026 ended June 30, 2025 and Provides Conference Call Information
Northvale, New Jersey--(Newsfile Corp. - August 14, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced results for the first quarter of fiscal year 2026 ended June 30, 2025 ("First Quarter").Consolidated revenues for the three-month period ending June 30, 2025, were $40.2 million, an increase of $21.4 million or approximately 114% as compared to the comparable period of the prior fiscal...
2025-08-14 4:24 PM EDT
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter 2026 Financial Results on August 15, 2025
Northvale, New Jersey--(Newsfile Corp. - August 8, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today that the first quarter financial results of the 2026 fiscal year will be released on Thursday, August 14, 2025. Elite's management will host a live conference call on Friday, August 15th, at 11:30 AM EDT to discuss the company's financial and operating results and provide a general...
2025-08-08 4:30 PM EDT
Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2025 and Provides Conference Call Information
Northvale, New Jersey--(Newsfile Corp. - June 30, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced results for the fiscal year ended March 31, 2025 ("Fiscal 2025").Consolidated revenues for Fiscal 2025 were $84.0 million, an increase of $27.4 million or approximately 48% as compared to the comparable period of the prior fiscal year. Operating profits were $19.6 million, an increase of...
2025-06-30 4:13 PM EDT
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Fiscal Year 2025 Financial Results on July 1, 2025
Northvale, New Jersey--(Newsfile Corp. - June 23, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today that it would release its 2025 year-end financial results on Monday, June 30, 2025. Elite's management will host a live conference call on Tuesday, July 1st, at 11:30 AM EDT to discuss the company's financial and operating results and provide a general business update. Stockholders...
2025-06-23 7:00 AM EDT
Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study
Northvale, New Jersey--(Newsfile Corp. - June 16, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, today reported positive results from a pivotal bioequivalence study for an undisclosed anticoagulant generic drug product.IQVIA reported branded product sales for the twelve months ending April 2025 of $27 billion. There is no generic product on the...
2025-06-16 7:00 AM EDT
Elite Pharmaceuticals Announces Commercial Launch of Oxycodone and Acetaminophen Tablets
Northvale, New Jersey--(Newsfile Corp. - April 30, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, today announced that the company has launched Elite's generic version of Percocet® (oxycodone hydrochloride and acetaminophen tablets, USP CII) 5mg/325mg, 7.5mg/325mg and 10mg/325mg tablets. Oxycodone HCl and acetaminophen is indicated for the relief of moderate to moderately severe pain.IQVIA...
2025-04-30 4:30 PM EDT
Elite Pharmaceuticals, Inc. Announces First Shipment of Product from New Facility and Packaging Line
Northvale, New Jersey--(Newsfile Corp. - March 3, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today the shipment of its first lot of finished product from its new FDA-approved expanded campus. The new facility, located at 144 Ludlow Avenue in Northvale, New Jersey, includes packaging, inventory and warehouse space. The new packaging line utilizes the latest technology, capable of...
2025-03-03 7:00 AM EST
Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2025 ended December 31, 2024 and Provides Conference Call Information
Northvale, New Jersey--(Newsfile Corp. - February 13, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, announced results for the three months ended December 31, 2024, which is the third quarter of the Company's fiscal year ending on March 31, 2025 ("Third Quarter").Consolidated revenues for the three months ended December 31, 2024, were $14.4...
2025-02-13 4:22 PM EST
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2025 Financial Results on February 14, 2025
Northvale, New Jersey--(Newsfile Corp. - February 10, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today that the third quarter financial results of the 2025 fiscal year will be released on Thursday, February 13, 2025. Elite's management will host a live conference call on Friday, February 14th, at 11:30 AM EST to discuss the company's financial and operating results and provide a...
2025-02-10 4:54 PM EST
Elite Pharmaceuticals Announces Commercial Launch of Generic Vyvanse(R)
Northvale, New Jersey--(Newsfile Corp. - December 26, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, today announced that the company has launched Elite's generic version of Vyvanse® (Lisdexamfetamine Disylate) with strengths of 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg and 70 mg capsules. The product is indicated for the treatment of attention deficit hyperactivity disorder (ADHD). This...
2024-12-26 7:00 AM EST
Elite Pharmaceuticals Announces Commercial Launch of Acetaminophen and Hydrocodone Tablets
Northvale, New Jersey--(Newsfile Corp. - December 2, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, today announced that the company has launched Elite's generic version of Norco® (hydrocodone bitartrate and acetaminophen tablets, USP CII) 2.5mg/325mg, 5mg/325mg, 7.5mg/325mg and 10mg/325mg tablets. Hydrocodone and acetaminophen is indicated for the management of pain severe enough to require...
2024-12-02 6:00 AM EST
Elite Pharmaceuticals Receives FDA Approval for Generic Vyvanse
Northvale, New Jersey--(Newsfile Corp. - November 18, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, today announced that it received approval from the US Food and Drug Administration (FDA) for an Abbreviated New Drug Application (ANDA) for a generic version of Vyvanse® (Lisdexamfetamine Dimesylate) with strengths of 10 mg, 20 mg, 30 mg, 40 mg,...
2024-11-18 6:00 AM EST
Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2025 Ended September 30, 2024 and Provides Conference Call Information
Northvale, New Jersey--(Newsfile Corp. - November 14, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, announced results for the three months ended September 30, 2024, which is the second quarter of the Company's fiscal year ending on March 31, 2025 ("Second Quarter").Consolidated revenues for the three months ended September 30, 2024, were $18.9...
2024-11-14 4:38 PM EST
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2025 Financial Results on November 15, 2024
Northvale, New Jersey--(Newsfile Corp. - November 7, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today that the second quarter financial results of the 2025 fiscal year will be released on Thursday, November 14, 2024. Elite's management will host a live conference call on Friday, November 15th, at 11:30 AM EST to discuss the company's financial and operating results and provide a...
2024-11-07 7:00 AM EST
Elite Pharmaceuticals' Generic Adderall(R) Receives Marketing Approval from the Israeli Ministry of Health
Northvale, New Jersey--(Newsfile Corp. - October 10, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, today announced the Israeli Ministry of Health approval for Elite's generic version of Adderall®, an immediate-release mixed salt of a single entity Amphetamine product (Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate) with strengths of 10 mg,...
2024-10-10 4:41 PM EDT
Elite Pharmaceuticals Announces Commercial Launch of Acetaminophen and Codeine Phosphate Tablets
Northvale, New Jersey--(Newsfile Corp. - October 7, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, today announced that the company has launched Elite's generic version of Tylenol® with Codeine (acetaminophen and codeine phosphate) 300mg/15mg, 300mg/30mg, and 300mg/60mg tablets.Acetaminophen and codeine phosphate tablets are indicated for the management of mild to moderate pain, where...
2024-10-07 7:30 AM EDT
Elite Pharmaceuticals Announces Commercial Launch of Generic Methotrexate Sodium
Northvale, New Jersey--(Newsfile Corp. - August 27, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, today announced that the company has launched Elite's generic methotrexate sodium 2.5 mg tablets. Methotrexate sodium tablets are a dihydrofolate reductase inhibitor indicated for the: Treatment of adults with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance...
2024-08-27 7:00 AM EDT